公开(公告)号：US11918662B2

公开(公告)日：2024-03-05

申请号：US17344582

申请日：2021-06-10

Applicant: CHDI Foundation, Inc.

Inventor： Longbin Liu ,  Matthew Lee ,  Celia Dominguez ,  Peter David Johnson ,  Catherine Jane Greenaway ,  Kanika Khurana ,  Matthew Robert Mills ,  Filippo Rota

IPC: A61K51/04 ,  C07B59/00 ,  C07D231/12 ,  C07D471/04 ,  C07D487/04 ,  C07D487/14 ,  C07D519/00

CPC classification number: A61K51/0459 ,  A61K51/0455 ,  A61K51/0463 ,  C07B59/002 ,  C07D231/12 ,  C07D471/04 ,  C07D487/04 ,  C07D487/14 ,  C07D519/00 ,  C07B2200/05

Abstract: Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.

公开(公告)号：US20220409600A1

公开(公告)日：2022-12-29

申请号：US17752683

申请日：2022-05-24

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Jonathan Bard ,  Matthew R. Lee ,  Longbin Liu ,  Michael Edward Prime ,  Samuel Coe

IPC: A61K31/454 ,  A61K47/54 ,  A61K31/165 ,  A61K31/427

Abstract: The present disclosure relates generally to compounds that simultaneously bind both mutant huntingtin protein (mHTT) and an ubiquitin E3 ligase and their use as therapeutic agents, for example, in treating diseases, such as neurodegenerative disorders caused by aggregation of mHTT.

公开(公告)号：US20220339302A1

公开(公告)日：2022-10-27

申请号：US17715661

申请日：2022-04-07

Applicant: CHDI Foundation, Inc.

Inventor： Longbin Liu ,  Celia Dominguez ,  Jonathan Bard ,  Christopher John Brown ,  Xuemei Chen ,  Daniel Clark-Frew ,  Matthew Robert Mills ,  Peter David Johnson ,  Elise Gadouleau

IPC: A61K51/04 ,  A61P25/28 ,  C07D401/14

Abstract: Provided herein are certain isoindolinone compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.

公开(公告)号：US20210393812A1

公开(公告)日：2021-12-23

申请号：US17344582

申请日：2021-06-10

Applicant: CHDI Foundation, Inc.

Inventor： Longbin Liu ,  Matthew Lee ,  Celia Dominguez ,  Peter David Johnson ,  Catherine Jane Greenaway ,  Kanika Khurana ,  Matthew Robert Mills ,  Filippo Rota

IPC: A61K51/04 ,  C07B59/00 ,  C07D487/04 ,  C07D487/14 ,  C07D519/00 ,  C07D231/12 ,  C07D471/04

Abstract: Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.

公开(公告)号：US11071793B2

公开(公告)日：2021-07-27

申请号：US15507214

申请日：2015-08-28

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  John Wityak ,  Jonathan Bard ,  Christopher John Brown ,  Thomas Martin Krülle ,  Daniel Clark-Frew ,  Sarah Hayes

IPC: A61K51/00 ,  A61M36/14 ,  A61K51/04 ,  C07D401/14 ,  C07D403/04 ,  C07D401/04 ,  C07D487/04 ,  C07D513/04 ,  C07D513/14

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

公开(公告)号：US10907197B2

公开(公告)日：2021-02-02

申请号：US15507217

申请日：2015-08-28

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  John Wityak ,  Jonathan Bard ,  Christopher John Brown ,  Michael Edward Prime ,  Derek Alexander Weddell ,  Daryl Simon Walter ,  Paul Richard Giles ,  Ian James Wigginton ,  Malcolm George Taylor ,  Sébastien René Gabriel Galan ,  Peter David Johnson ,  Thomas Martin Krülle ,  Inaki Morao ,  Daniel Clark-Frew

IPC: C07D253/08 ,  C07D401/04 ,  C07D473/00 ,  C12Q1/6823 ,  A61K51/04

Abstract: Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.

公开(公告)号：US10479802B2

公开(公告)日：2019-11-19

申请号：US15507208

申请日：2015-08-28

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Samuel Coe ,  Jonathan Bard ,  Peter David Johnson ,  Michael Edward Prime ,  Christopher John Brown ,  Sébastien René Gabriel Galan ,  Paul Richard Giles ,  Elise Luciennen Paulette Gadouleau ,  Thomas Martin Krülle ,  Daniel Clark-Frew ,  John Wityak ,  Alex Kiselyov ,  Sarah Hayes

IPC: C07D513/04 ,  C07D413/14 ,  C07D471/04 ,  A61K51/04 ,  C07D413/12 ,  C07D263/57 ,  C07D498/04 ,  C07D405/14 ,  C07D413/04

Abstract: Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.

公开(公告)号：US20190062321A1

公开(公告)日：2019-02-28

申请号：US16049482

申请日：2018-07-30

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Ignacio Muñoz-Sanjuán ,  Roland W. Bürli ,  Christopher A. Luckhurst ,  Daniel R. Allen ,  Gilles Raphy ,  Perla Breccia ,  Alan F. Haughan ,  Grant Wishart ,  Samantha J. Hughes ,  Rebecca E. Jarvis ,  Huw D. Vater ,  Stephen D. Penrose ,  Michael Wall ,  Andrew J. Stott ,  Elizabeth A. Saville-Stones

IPC: C07D417/04 ,  C07D275/04 ,  C07D231/56 ,  C07C259/08 ,  C07D277/60 ,  C07D231/54 ,  C07D239/74 ,  C07D239/70 ,  C07D403/04 ,  C07D401/04 ,  C07D239/88

CPC classification number: C07D417/04 ,  C07C259/08 ,  C07D231/54 ,  C07D231/56 ,  C07D239/70 ,  C07D239/74 ,  C07D239/88 ,  C07D275/04 ,  C07D277/60 ,  C07D401/04 ,  C07D403/04

Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use.

公开(公告)号：US20190047977A1

公开(公告)日：2019-02-14

申请号：US15948821

申请日：2018-04-09

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Leticia Toledo-Sherman ,  Michael Prime ,  William Mitchell ,  Naomi Went

IPC: C07D327/06 ,  C07D319/16 ,  C07D311/02 ,  C07D311/04 ,  C07D263/58 ,  C07D235/26 ,  C07D215/06 ,  C07D307/79 ,  C07D211/72 ,  C07D263/38 ,  C07D233/70 ,  C07D319/18 ,  C07D317/62 ,  C07D317/46 ,  C07D317/50

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：US20180222838A1

公开(公告)日：2018-08-09

申请号：US15813001

申请日：2017-11-14

Applicant: CHDI Foundation, Inc.

Inventor： Leticia M. Toledo-Sherman ,  Celia Dominguez ,  Michael Prime ,  William Leonard Mitchell ,  Peter Johnson ,  Naomi Went

IPC: C07C62/38 ,  C07H15/20 ,  C07D203/10 ,  C07C69/757 ,  C07D307/80 ,  C07D307/54 ,  C07D305/08 ,  C07D305/06 ,  C07D295/155 ,  C07D207/337 ,  C07D271/07 ,  C07D207/08 ,  C07C235/82 ,  C07D263/58 ,  C07D203/08 ,  C07D257/04 ,  C07C229/48 ,  C07C229/46 ,  C07C229/22 ,  C07C323/62 ,  C07D413/10 ,  C07D413/08 ,  C07C317/44 ,  C07D405/12 ,  C07D405/10 ,  C07D405/08 ,  C07D403/10 ,  C07D235/26 ,  C07D233/64 ,  C07D319/18 ,  C07D317/60 ,  C07D317/46 ,  C07D311/58 ,  C07D215/18 ,  C07D309/10 ,  C07D307/94 ,  C07D307/79 ,  C07D413/12

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.